Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
Status:
Completed
Trial end date:
2018-02-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess safety and efficacy of brentuximab vedotin in
combination with bendamustine in patients with relapsed or refractory Hodgkin lymphoma. It is
an open-label, 2-stage study designed to determine the recommended dose level of bendamustine
in combination with brentuximab vedotin. The study will assess the safety profile of the
combination treatment and determine what proportion of patients achieve a complete remission.